Inhibition of glycolysis by a novel EGFR/HER2 inhibitor KU004 suppresses the growth of HER2+ cancer
Sign Up to like & getrecommendations! Published in 2017 at "Experimental Cell Research"
DOI: 10.1016/j.yexcr.2017.05.019
Abstract: &NA; Upregulation of glycolysis was often observed in human HER2‐overexpressing cancers. In this study, we demonstrated that KU004, a dual novel EGFR/HER2 inhibitor, disrupted cancer cell proliferation via modulation of glycolysis. KU004, inhibited the Warburg… read more here.
Keywords: egfr her2; ku004; glycolysis; novel egfr ... See more keywords
Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
Sign Up to like & getrecommendations! Published in 2020 at "Signal Transduction and Targeted Therapy"
DOI: 10.1038/s41392-020-00251-2
Abstract: Epidermal growth factor receptor (EGFR) activation plays a pivotal role in EGFR-driven non-small cell lung cancer (NSCLC) and is considered as a key target of molecular targeted therapy. EGFR tyrosine kinase inhibitors (TKIs) have been… read more here.
Keywords: dpba; egfr; novel egfr; egfr ligand ... See more keywords
Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study
Sign Up to like & getrecommendations! Published in 2023 at "Molecules"
DOI: 10.3390/molecules28073014
Abstract: Targeting L858R/T790M and L858R/T790M/C797S mutant EGFR is a critical challenge in developing EGFR tyrosine kinase inhibitors to overcome drug resistance in non-small cell lung cancer (NSCLC). The discovery of next-generation EGFR tyrosine kinase inhibitors (TKIs)… read more here.
Keywords: type mutant; novel egfr; type; egfr inhibitor ... See more keywords